Within the group of gout patients we observed no differences between intercritical and flaring patients. We observed no significant difference in receptor expression or TGFB1, ITGAV and SMAD7, but the downstream target MMP9 was increased in patients with gout compared to controls (Fig. 2A-D). The gene discussed is TGFB1; the disease is gout.